eral options that make patient monitoring and online hemodiafi ltration therapy routine procedures. These and other features will possibly make dialysis better tolerated and more effi cient in protecting patients from undesirable or potentially fatal cardiovascular events.
Introduction
Complications associated with hemodialysis (HD) mostly involve the cardiovascular system. Patients present higher mortality rates compared with the general population, which is attributed to cardiovascular disorders including heart failure, coronary heart disease, and peripheral vascular disease [1] [2] [3] [4] [5] . Today, the challenge of new technologies in HD is related to the capacity of completely, or at least partly, overcoming the severe metabolic and clinical disorders that lead to major cardiovascular events [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . New technology in dialysis cannot modify the factors intrinsic to the patient such as diabetes or genetic abnormalities but it should at least consider the possibility of favorably modifying some of the other risk factors implicated in the genesis of cardiovascular disorders such as anemia, chronic infl ammation, oxidative stress, and advanced glycation end products (AGEs). Lifestyle-associated risk factors such as smoking, obesity and inactivity should be considered separately.
Traditional and Non-Traditional Cardiovascular Risk Factors
The uremic state per se contributes to the bulk of the risk of cardiovascular disease in HD patients, and in this setting, infl ammation plays a crucial role. Furthermore, most HD patients suffer from one or a number of comorbid conditions such as hypertension and diabetes that exacerbate uremia and vice versa. The cardiovascular burden carried by dialysis patients is multi-factorial and can thus be increased when uremia-related and traditional risk factors (affecting the general population) are combined. A third source of contribution to the overall cardiovascular burden could be the inadvertent and adverse infl uence of certain features related to the dialysis procedure.
Oxidant Stress, Infl ammation and Accelerated Atherosclerosis
End-stage renal disease (ESRD) patients suffer from a state of chronic infl ammation leading to cardiovascular complications, progressive malnutrition, and death [19] [20] . Infl ammation is subclinical, and chronic disorders of the cytokine system or acute phase proteins may be observed as the sole evidence of a proinfl ammatory disorder [21, 22] .
There are several reasons why HD patients are associated with chronic infl ammation. The condition of uremia per se is characterized by a series of metabolic disturbances that produce an imbalance between immunostimulation and immunodepression. There is a disequilibrium between the production of reactive oxygen species and the antioxidant defense of the organism [23] . The HD membrane together with several other components of the dialysis may lead to a condition of subclinical, progressive infl ammation. However, cardiovascular disease is often already present in asymptomatic patients with renal failure and on conservative treatment [24] . This may also be exacerbated by other comorbid states including infections, periodontal disease, and atherosclerosis [25] [26] [27] [28] .
All these factors seem to combine their action to produce long-term clinical derangements. In particular, the production of proinfl ammatory cytokines as a response to a specifi c stimulus increases the level of acute phase reactants -C-reactive protein (CRP), fi brinogen, serum amyloid A, transferrin -triggering a cascade of events including endothelial dysfunction, accelerated atherogenesis, and cardiovascular disease [25] [26] [27] [28] . Mortality, morbidity and hospitalization are positively correlated with the serum acute phase proteins such as CRP, serum amyloid A, and soluble adhesion molecules, as well as with the cytokines that regulate them (IL-6), in HD patients as well as in the general population [21] [22] [23] [24] [25] [26] [27] .
Leptin and ␤ 2 -microgobulin are molecules in the middle weight range considered important factors in accelerating the cardiovascular damage in ESRD patients. Dyslipidemia, bioincompatibility of dialysis membranes, oxidative stress and anemia are other important risk factors involved in the aggravation of cardiovascular disorders, and again, high-molecular weight erythropoiesis inhibitors have been demonstrated to play an important role in this disorder.
The Additional Burden of Potentially Contaminated Dialysate
Contaminated dialysis fl uid, or water quality, are further important issues, together with the silent chronic infl ammation and the formation of AGEs. There are infl ammatory disorders which are thought to contribute to the pathogenesis of atherosclerosis in HD patients. AGEs act synergistically with endotoxins, and the cytokine-inducing effect of AGEs plus endotoxin is more potent than the effect of either alone. In conclusion, ESRD patients are at risk for cardiovascular disease, and early atherosclerotic lesions seem to contribute to negative outcomes. What can we do to correct or prevent such conditions and possibly improve the outcome? Is modern technology able to respond in a positive way to this challenge?
The Challenge of New Technologies and Biomaterials
The application of new technologies involves the use of new biomaterials designed to ameliorate dialyzer and membrane performance, the application of these advanced dialyzers in therapeutic modalities that attempt to exploit the maximal capacity of blood purifi cation procedures involving different mechanisms including convection, and the utilization of dialysis machines whose functions are well integrated in the concepts of safety, quality of therapy, performance, easy monitoring, and having a friendly user interface.
It is well known that modern high-fl ux dialyzers can effi ciently remove different-sized uremic retention solutes [31, 32] . Wanner et al. [33] , in a randomized cross-over study (36 patients) , showed the infl uence of dialyzer fl ux and membrane material on the three cardiovascular disease risk factors. Patients showed improved lipid and apolipoprotein profi les after 6 weeks of high-fl ux treatment. In particular, levels of oxidized low-density lipoprotein were signifi cantly reduced when treated with the new Helixone polysulfone membrane in comparison with the cellulose triacetate membrane. The essential features of contemporary dialysis membranes have recently been improved through the application of novel nanotechnology principles during the process of membrane spinning, especially involving the controlled precipitation step that defi nes the fi ne structure of the hollow-fi ber membrane wall [34] [35] [36] .
There is evidence for benefi cial effects of high-fl ux dialysis (compared with low-fl ux dialysis) in controlling renal anemia and reducing the cost of the therapy, an effect probably achieved by the effi cient removal of middle-and high-molecular weight erythropoiesis inhibitors [37] . A number of papers have shown that endotoxin elimination from dialysis fl uids necessitates the usage of effi cient water treatment systems as well as dialyzer membranes having a high endotoxin retention capacity. Modern dialysis machines, in conjunction with advanced water treatment systems, facilitate the achievement of ultrapure dialysate through multiple steps of fi ltration occurring in specifi c fi lters placed in the dialysate circuit of the machine [38] .
Two recent publications have highlighted the membrane material-dependent retention of endotoxins from contaminated dialysate. Weber et al. [39] showed that polysulfone-based membranes had a signifi cantly higher endotoxin retention compared with two polyarylethersulfone-based membranes. Likewise, Schindler et al. [40] demonstrated differences in the permeability of high-fl ux dialyzer membranes for bacterial pyrogens, concluding that dialyzers that leak cytokine-inducing substances should not be used unless the dialysate has passed through an ultrafi lter.
An association between ultrapure dialysate and iron utilization and erythropoietin response in chronic HD patients has recently been published [41, 42] . Endotoxin reduction by cold fi ltration led to reduced CRP plasma levels, reduced EPO dose, and improved iron utilization.
Today, based on these studies and observations, one can approach dialysis therapy with the attempt not only to reduce the level of uremic intoxication, but also to implement a series of potentially cardioprotective measures and treatment modalities.
From Ultrapure Dialysate to Online Hemodiafi ltration
Treatment modalities that involve convection, rather than diffusion, as the predominant mechanism of uremic toxin removal are increasingly being acknowledged as more relevant in that, like the natural kidney, a broader spectrum of uremic retention solutes are removed. Further, it is now becoming apparent that signifi cant additional advantages can be attributed to therapy modalities, such as hemodiafi ltration (HDF), which more effi ciently eliminate middle molecules [43, 44] and point towards improving patient outcomes. However, the increased removal of middle molecules might be associated with a high leakage of essential substances like albumin from the patient's blood, thereby perhaps compromising the nutritional status of the patient. For this reason, new membranes with nanocontrolled characteristics are increasingly used to achieve the maximal benefi ts from a large removal of middle molecules but minimizing the loss of important nutrients such as albumin [45, 46] . These new membranes take the maximal advantage of convection, and therefore, high volume exchanges are used to maximally exploit the capacity of the membrane. For this reason, online hemofi ltration is the therapy of choice in providing effi cient removal of a wide spectrum of molecules.
Another issue of concern in contemporary dialysis therapy is how to cope with severe fl uctuations of physiological processes during a single dialysis session, as well as in the intradialytic interval. Dialysis profi ling is now being recognized as highly useful in providing quality assurance through monitoring of the therapy during each and every dialysis session. Further, it also reduces the incidence and occurrence of severe unphysiological events, thereby ensuring safety to the dialysis care team as well as the patient, and possibly provides a favorable infl uence on patient outcomes [47] .
Cardioprotective Hemodialyis: The Role for a 'New' Dialysis Machine
The Hemodialysis study showed a 20% reduction in cardiac death and a 13% decrease in the composite of fi rst cardiac hospitalization or cardiac death as a result of high-fl ux dialysis compared with low-fl ux dialysis [48] . Improving biocompatibility and solute removal by convection and reducing the burden of HD on hypo-/hypertension, salt and water overload and left ventricular hy- pertrophy are the cornerstones of 'cardioprotective dialysis'. Thus, the creation of a new dialysis machine must take into account all those features that might affect the fi nal outcome, or at least, contribute towards the concept of performing 'cardioprotective dialysis' ( fi g. 1 ) Treatment-related variations relate to changes in the concentration of uremic retention solutes (e.g., urea) as well as to the volume status/dry weight of the patient: these variations are monitored and accounted for with specifi c tools integrated in the dialysis machine. The online clearance monitoring relies on the measurement of the ionic strength of the dialysate and is then correlated to urea clearance; this is required for the estimation of the dose of dialysis (Kt/V), an index that is associated with patient outcomes. The online clearance monitoring also measures the plasma Na + concentration of the patient, thus enabling the attending nephrologist to individualize the prescription with respect to the dialysate Na + concentration. Blood volume measurement contributes to monitor the circulating volume, to maintain normovolemia, and to reach dry weight. In general, the uremic population is confronted with vascular impairment attributed to arterial stiffness, making it harder to regulate the fl uid status/regulation. This aspect of vascular dysfunction is further aggravated by dialysis therapies when large unphysiological changes in hemodynamic responses occur in response to rapid fl uid removal by ultrafi ltration; attaining normovolemia in a controlled, gradual manner would clearly be less damaging to the patient [49, 50] . Online blood volume monitoring helps regulate the fl uid removal during the treatment: ideally, the ultrafi ltration rate is adjusted automatically, preferably according to the patient's plasma refi lling rate. Clinical studies have demonstrated the usefulness of blood volume monitoring in reducing hypotensive episodes [51] . The maintenance of an adequate vascular tone and sympathetic response has been correlated with the thermal energy balance during dialysis. The online blood temperature monitor permits the regulation and stabilization of intradialytic body temperature, thereby achieving cardiovascular stability; its application has been shown to have a considerable positive effect on the intradialytic vascular stability [52] .
From Expensive Technical Gadgets to Useful Tools for Routine Monitoring
Today, online HDF is already a widespread and wellaccepted treatment modality. It is also the dialysis modality for which more technology has been produced and inventiveness articulated [53] . At the time of writing, data from 4,504 patients followed from 1998 to 2001 in fi ve European countries (in the course of the Dialysis Outcomes and Practice Patterns Study) are being reanalyzed. Preliminary results show that after adjustment of patient demographics and comorbid conditions, patients receiving online HDF appear to have a signifi cantly reduced risk of mortality. In an initial presentation of these data, a 23% reduction in mortality was described [54] . However, this reduction was smaller than in reality, since data from online HDF (20-24 liters), HDF with 10-20 liters and HDF with 6-10 liters were all computed together, leading to no signifi cant reduction. A reduced risk of mortality has also been shown preliminarly in the Euclid ® database based on data from the Fresenius Medical Care Clinics in Europe [55] [56] . Apart from other forms of HDF (acetate-free biofi ltration, push-pull, mid-dilution, paired fi ltration dialysis), online HDF has constantly increased its popularity, possibly based on the following facts. Firstly, the unlimited amount of fl uid which can be produced online under proven and experience-based safety protocols will further encourage the application of increased convection [57] . New perspectives in the use of pre-and postinfusion, controlled by the transmembrane pressure ultrafi ltration feedback, may enable a more complete exploitation of the convective mechanism [58] . Secondly, the 5008 machine, the most recent dialysis machine customized specifi cally for online HDF, will help improve the hemodynamic instability and fulfi ll the new concept of online HDF as a cardioprotective modality.
Online HDF thus appears to set new standards in patients' quality care and a better way to exploit present and future technology. The repercussion will contribute to an ever wider acceptance not only of online HDF but in reducing the negative effects of contaminated dialysate, still very prevalent today in most dialysis units, used in conventional HD. As has been the case in the past also for online HDF, the advantages will counterbalance drawbacks [59] . As the Agence nationale d'accréditation et d'évaluation en santé has stated '… processes for establishing and maintaining the quality of their water treatment should be installed in order to insure that monitoring and prevention be put into practice ' [60] . This implies the combined effort of nephrologists, pharmacists, hospital bioengineers, and industry in a team work attitude. Public agencies will have the duty to check and accredit validated protocols in each center. This is even more important in the light of a decreased risk of mortality being associated with high convective online HDF. This is exactly how HD has evolved since its early days and how it can be further developed. Thirdly, full automation of the dialysis machine will open the practical adoption of daily online HDF of which the clinical benefi ts have been already reported. In conclusion, the new step in technology provided by the 5008 machine is not simply the introduction of new series of features provided by the machine, but rather the possibility of using all these new features as a routine for an improved effi ciency and tolerance for the patient [61] .
